Safety and Early Immune Dynamics Following First Dose of the MMR Vaccine in a Toddler Treated With a JAK Inhibitor.
Despoina Maritsi, Ariadni Neofytou, Maria Papadimitriou et al.
✦ AI-curated · Sources linked
Case in brief
A toddler receiving baricitinib was accidentally given the live measles-mumps-rubella (MMR) vaccine. No vaccine-related adverse events were reported. The child developed a satisfactory antibody response to measles, mumps, and rubella, which remained present at 6-month follow-up despite continued Janus kinase inhibitor therapy.
What made this case unusual
The case documents both the absence of reported vaccine-related adverse events and a sustained antibody response after accidental administration of a live vaccine during ongoing baricitinib treatment.
Diagnostic / clinical pearl
After accidental live MMR vaccination during baricitinib therapy, this child had no reported vaccine-related adverse events and maintained antibody responses at 6 months; a single case cannot establish general safety.